![Sven Kili](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sven Kili
Président chez
Sven Kili Consulting Ltd.
Profil
Sven is an advisor to Saisei Ventures, participating in the investment process as a contributor to the investment advisory committee.
He was previously the CEO of Antion S.A., A Swiss-based allogeneic CAR-T biotech company and Head of Development for the CGT division of GSK Rare Diseases where he led teams developing and commercialising gene therapies for a variety of rare genetic disorders including Strimvelis®, the first ex-vivo gene therapy to be approved for children with ADA-SCID; Wiskott - Aldrich syndrome (WAS); Metachromatic Leukodystrophy (MLD) and Beta- Thalassemia and others.
Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development, approval and commercialisation activities of the first combined ATMP product in the EU for MACI®.
He and his team also prepared and submitted various Advanced Therapy regulatory filings for Australia and the US, including health technology assessments and he was responsible for late stage developments for Carticel® and Epicel® in the US.
Before joining Genzyme, Sven led the cell therapy activities and oversaw all UK & Irish regulatory functions and was the QPPV for pharmacovigilance for the Geistlich Pharma.
Sven trained as an Orthopaedic surgeon in the UK and South Africa and since leaving full-time clinical practise has developed expertise Cell and Gene Therapy strategic company formation, clinical development, regulatory compliance, value creation, risk management and product safety, product launches and post-marketing activities.
Postes actifs de Sven Kili
| Sociétés | Poste | Début |
|---|---|---|
Sven Kili Consulting Ltd. | Président | - |
Centre For Commercialization of Regenerative Medicine
 Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Provides regenerative medicine-based technologies and cell and gene therapy | Directeur/Membre du Conseil | 01/01/2017 |
Standards Coordinating Body
 Standards Coordinating Body The Standards Coordinating Body is a nonprofit organization focused on accelerating the development, awareness, and implementation of standards and best practices in regenerative medicine, including gene, cell, and advanced therapies. The private company is based in Gaithersburg, MD. It engages stakeholders such as government agencies, researchers, manufacturers, clinicians, and regulators to identify, prioritize, and advance standards that improve the safety, quality, efficacy, and availability of regenerative medicine products. The organization facilitates collaborative project working groups that develop feasibility studies, standards drafts, white papers, and coordinate data generation activities in areas like cell-based drug discovery, cell therapy, gene therapy, and tissue engineering. It offers specialized training programs on FDA-recognized ISO cell counting standards, including online and in-person courses, and provides resources such as an interactive database for exploring current and developing standards and educational materials. | Directeur/Membre du Conseil | - |
Saisei Ventures LLC
 Saisei Ventures LLC Investment ManagersFinance Saisei Ventures invests in companies located across the globe. The firm focuses on the biotechnology sector with a focus on advanced therapies such as cell and gene therapies and regenerative medicines. It participates in seed and early stage transactions. | Consultant / Advisor | 01/09/2023 |
Anciens postes connus de Sven Kili
| Sociétés | Poste | Fin |
|---|---|---|
| XINTELA AB | Directeur Technique/Scientifique/R&D | 01/05/2022 |
Geistlich Biomaterials Vertriebsgesellschaft mbH
 Geistlich Biomaterials Vertriebsgesellschaft mbH Medical/Nursing ServicesHealth Services Provides biomaterials for medical and dental use | Consultant / Advisor | 30/05/2018 |
Antion Biosciences SA
 Antion Biosciences SA BiotechnologyHealth Technology Develops allogeneic therapies | Directeur Général | - |
GlaxoSmithkline AB
 GlaxoSmithkline AB Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | - |
Genzyme Biosurgery Corp.
 Genzyme Biosurgery Corp. BiotechnologyHealth Technology Develops and manufactures biotherapeutic and biomaterial products | Directeur Technique/Scientifique/R&D | - |
Formation de Sven Kili
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
11
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Genzyme Biosurgery Corp.
Genzyme Biosurgery Corp. BiotechnologyHealth Technology Develops and manufactures biotherapeutic and biomaterial products | Health Technology |
University of Stellenbosch
 University of Stellenbosch Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithkline AB
GlaxoSmithkline AB Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Geistlich Biomaterials Vertriebsgesellschaft mbH
Geistlich Biomaterials Vertriebsgesellschaft mbH Medical/Nursing ServicesHealth Services Provides biomaterials for medical and dental use | Health Services |
The Royal College of Surgeons of England
 The Royal College of Surgeons of England Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xintela AB
 Xintela AB BiotechnologyHealth Technology Provides treatment and medicine for articular cartilage injuries and diseases | Health Technology |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Provides regenerative medicine-based technologies and cell and gene therapy | Health Technology |
Sven Kili Consulting Ltd. | |
Antion Biosciences SA
Antion Biosciences SA BiotechnologyHealth Technology Develops allogeneic therapies | Health Technology |
Standards Coordinating Body
Standards Coordinating Body The Standards Coordinating Body is a nonprofit organization focused on accelerating the development, awareness, and implementation of standards and best practices in regenerative medicine, including gene, cell, and advanced therapies. The private company is based in Gaithersburg, MD. It engages stakeholders such as government agencies, researchers, manufacturers, clinicians, and regulators to identify, prioritize, and advance standards that improve the safety, quality, efficacy, and availability of regenerative medicine products. The organization facilitates collaborative project working groups that develop feasibility studies, standards drafts, white papers, and coordinate data generation activities in areas like cell-based drug discovery, cell therapy, gene therapy, and tissue engineering. It offers specialized training programs on FDA-recognized ISO cell counting standards, including online and in-person courses, and provides resources such as an interactive database for exploring current and developing standards and educational materials. | |
Saisei Ventures LLC
Saisei Ventures LLC Investment ManagersFinance Saisei Ventures invests in companies located across the globe. The firm focuses on the biotechnology sector with a focus on advanced therapies such as cell and gene therapies and regenerative medicines. It participates in seed and early stage transactions. | Finance |
